



# Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

Hardik Goswami<sup>1,7</sup> · Adnan Alsumali<sup>1</sup> · Yiling Jiang<sup>2</sup> · Matthias Schindler<sup>3</sup> · Elizabeth R. Duke<sup>4</sup> · Joshua Cohen<sup>5</sup> · Andrew Briggs<sup>6</sup> · Amy Puenpatom<sup>1</sup>

Published online: 16 March 2023  
© The Author(s) 2023

**Correction to: PharmacoEconomics 40, 699–714 (2022)**  
<https://doi.org/10.1007/s40273-022-01168-0>

The following sentence was erroneously omitted from the Acknowledgements section of the article:

The authors thank Alvin Ng, Alex Porteous, Faye Saville, Flo Anderson and Jennifer Page, employees of Costello Medical, Cambridge, UK, for deriving the US utility values employed in the analysis.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

---

The original article can be found online at <https://doi.org/10.1007/s40273-022-01168-0>.

---

✉ Hardik Goswami  
[hardik.goswami@merck.com](mailto:hardik.goswami@merck.com)

<sup>1</sup> BARDS-Health Economics and Decision Science, Merck & Co, Inc., Kenilworth, NJ, USA

<sup>2</sup> BARDS-Health Economics and Decision Science MSD (UK) Ltd, London, UK

<sup>3</sup> BARDS-HTA, MSD Ltd, Zurich, Switzerland

<sup>4</sup> Fred Hutchinson Cancer Research Center, Seattle, WA, USA

<sup>5</sup> Center for the Evaluation of Value and Risk in Health, Boston, MA, USA

<sup>6</sup> London School of Hygiene and Tropical Medicine, London, UK

<sup>7</sup> BARDS-Health Economics and Decision Science, Merck & Co, Inc., 770 Sumneytown Pike, West Point, PA 19486, USA